0000950157-13-000077.txt : 20130213 0000950157-13-000077.hdr.sgml : 20130213 20130213163739 ACCESSION NUMBER: 0000950157-13-000077 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130213 DATE AS OF CHANGE: 20130213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Prothena Corp plc CENTRAL INDEX KEY: 0001559053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87112 FILM NUMBER: 13603790 BUSINESS ADDRESS: STREET 1: 25-28 NORTH WALL QUAY CITY: DUBLIN STATE: L2 ZIP: DUBLIN 1 BUSINESS PHONE: 353 1 709 4700 MAIL ADDRESS: STREET 1: 25-28 NORTH WALL QUAY CITY: DUBLIN STATE: L2 ZIP: DUBLIN 1 FORMER COMPANY: FORMER CONFORMED NAME: Neotope Corp Ltd DATE OF NAME CHANGE: 20120926 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1212 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 SC 13G 1 sc13g.htm SCHEDULE 13G sc13g.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
(Amendment No.  )*
 
Prothena Corporation plc
(Name of Issuer)
 
Ordinary Shares, Par value $0.01 each (Ordinary Shares)
 
(Title of Class of Securities)
 
G72800 10 8
(CUSIP Number)
 
 
December 14, 2012
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨           Rule 13d-1(b)

¨           Rule 13d-1(c)

x           Rule 13d-1(d)
 
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

 
 
 
 

 
CUSIP No.
G72800 10 8
13G
  

 
1
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Johnson & Johnson
I.R.S. I.D. # 22-1024240
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)  ¨
(b)  x
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
New Jersey
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
2,619,421
6
SHARED VOTING POWER
 
-0-
7
SOLE DISPOSITIVE POWER
 
2,619,421
8
SHARED DISPOSITIVE POWER
 
-0-
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,619,421
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
 
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
14.82%*
12
TYPE OF REPORTING PERSON (See Instructions)
 
CO

* Based on 17,679,182 outstanding Ordinary Shares, which is the total number of Ordinary Shares outstanding as of December 20, 2012 (as reported on Prothena Corporation plc’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission on December 21, 2012).
 
 
 
 
 
 
 
Item 1.
    
     
 
(a)
Name of Issuer: Prothena Corporation plc
     
 
(b)
Address of Issuer’s Principal Executive Offices:
     
   
650 Gateway Boulevard, South San Francisco, California 94080
Item 2.
    
 
(a)
Name of Person Filing:
     
   
Johnson & Johnson, a New Jersey corporation
     
 
(b)
Address of Principal Business Office or, if none, Residence:
     
   
One Johnson & Johnson Plaza, New Brunswick, NJ 08933
     
 
(c)
Citizenship: New Jersey
     
 
(d)
Title of Class of Securities: Ordinary Shares, Par value $0.01 each (Ordinary Shares)
     
 
(e)
CUSIP Number: G72800 10 8
     
Item 3.
 If this statement is filed pursuant to §§240.13d–1(b), or 240.13d–2(b) or (c), check whether the person filing is a:
       
 
(a)
¨
Broker or dealer registered under section 15 of the Act;
       
 
(b)
¨
Bank as defined in section 3(a)(6) of the Act;
       
 
(c)
¨
Insurance company as defined in section 3(a)(19) of the Act;
       
 
(d)
¨
Investment company registered under section 8 of the Investment Company Act of 1940;
       
 
(e)
¨
An investment adviser in accordance with §§240.13d–1(b)(1)(ii)(E);
       
 
(f)
¨
An employee benefit plan or endowment fund in accordance with §§240.13d–1(b)(1)(ii)(F);
       
 
(g)
¨
A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);
       
 
(h)
¨
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
       
 
(i)
¨
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
       
 
(j)
¨
A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J).
       
 
(k)
¨
Group, in accordance with §240.3d–1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:
       
     
If this statement is filed pursuant to Rule 13d-1(c), check this box. ¨
 
 
 
 
 
 
 
Item 4.
Ownership.
  
     
 
(a)
Amount beneficially owned: 2,619,421
     
 
(b)
Percent of class: 14.82%*
     
   
* Based on 17,679,182 outstanding Ordinary Shares, which is the total number of Ordinary Shares outstanding as of December 20, 2012 (as reported on Prothena Corporation plc’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission on December 21, 2012).
     
 
(c)
Number of shares to which the person has:
     
   
(i)
Sole power to vote or to direct the vote:  2,619,421
     
   
(ii)
Shared power to vote or to direct the vote:  0
     
   
(iii)
Sole power to dispose or to direct the disposition of:  2,619,421
     
   
(iv)
Shared power to dispose or to direct the disposition of:  0
     
Item 5.
Ownership of Five Percent or Less of a Class.
   
 
Not applicable.
   
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
   
The 2,619,421 Ordinary Shares identified in Item 4 above are directly owned by Janssen Pharmaceutical, an Irish unlimited company (Reg. No. 79963), with its registered office at Little Island Industrial Estate, Little Island, Co. Cork, Ireland, a wholly owned subsidiary of Johnson & Johnson.
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
   
The 2,619,421 Ordinary Shares identified in Item 4 above are directly owned by Janssen Pharmaceutical, an Irish unlimited company (Reg. No. 79963), with its registered office at Little Island Industrial Estate, Little Island, Co. Cork, Ireland, a wholly owned subsidiary of Johnson & Johnson.
   
Item 8.
Identification and Classification of Members of the Group.
   
 
Not applicable.
   
Item 9.
Notice of Dissolution of Group.
   
 
Not applicable.
   
Item 10.
Certification.
   
 
Not applicable.
 
 
 
 
 

 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
Date: February 13, 2013
 
 
JOHNSON & JOHNSON,
  
       
 
By:
/s/ Douglas K. Chia  
    Name: Douglas K. Chia  
    Title:   Secretary